Oral Treatment for Type 2 Diabetes
First-Line Therapy: Metformin
Metformin is the recommended first-line oral pharmacologic agent for adults with type 2 diabetes when lifestyle modifications alone fail to achieve glycemic control. 1
Initial Dosing and Titration
Start metformin at 500 mg once or twice daily with meals to minimize gastrointestinal side effects, which are the most common reason patients discontinue therapy. 2, 3
Increase the dose by 500 mg increments every 7 days as tolerated until reaching the target dose of 2000 mg daily (typically 1000 mg twice daily for immediate-release or 2000 mg once daily for extended-release formulations). 2, 3
Extended-release metformin should be taken once daily with the evening meal, which improves adherence and may reduce gastrointestinal intolerance compared to immediate-release formulations. 2
The maximum FDA-approved dose is 2550 mg daily, though most patients achieve adequate control at 2000 mg daily. 2
Renal Function-Based Dosing
Metformin dosing must be adjusted based on estimated glomerular filtration rate (eGFR) to prevent drug accumulation and lactic acidosis risk: 2, 3
| eGFR (mL/min/1.73 m²) | Dosing Recommendation | Monitoring Frequency |
|---|---|---|
| ≥60 | Continue standard dosing up to 2000-2550 mg daily | Annually |
| 45-59 | Continue current dose; do not initiate if not already on therapy; reassess risk/benefit | Every 3-6 months |
| 30-44 | Reduce dose to maximum 1000 mg daily (50% reduction) | Every 3-6 months |
| <30 | Discontinue metformin immediately (absolute contraindication) | — |
Absolute Contraindications
Do not prescribe metformin in the following situations: 2, 3, 4
- eGFR <30 mL/min/1.73 m²
- Acute or chronic metabolic acidosis
- Severe liver disease or active hepatic dysfunction
- Acute heart failure or hemodynamic instability
- Conditions causing tissue hypoxia (sepsis, severe respiratory insufficiency)
- Active alcohol abuse
- History of lactic acidosis
Temporary Discontinuation Required
Hold metformin immediately during: 2
- Acute illnesses causing volume depletion (severe vomiting, diarrhea, dehydration, sepsis)
- Hospitalizations with acute kidney injury risk
- Iodinated contrast procedures (hold 48 hours before and after; recheck eGFR before restarting)
Monitoring Requirements
Check eGFR before initiating metformin and at least annually if eGFR ≥60 mL/min/1.73 m². 2, 3
Increase monitoring to every 3-6 months when eGFR falls below 60 mL/min/1.73 m². 2, 3
Assess vitamin B12 levels periodically in patients on metformin for more than 4 years, especially those with anemia or peripheral neuropathy, as approximately 7% develop deficiency. 2, 3
Second-Line Oral Agents
When to Add a Second Agent
Reassess hemoglobin A1c 3 months after achieving the target metformin dose (2000 mg daily). 2 If A1c remains >7% (or above the individualized target), add a second agent. 2
Exception: If presenting with severe hyperglycemia (A1c ≥10% or random glucose ≥300 mg/dL with symptoms), consider dual therapy or insulin immediately without waiting 3 months. 2
Choice of Second-Line Agent
The selection of a second oral agent depends critically on the presence of specific comorbidities: 1
For Patients WITH Established Cardiovascular Disease, Heart Failure, or Chronic Kidney Disease (eGFR ≥30):
Add an SGLT-2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit as the preferred second agent, independent of A1c level. 2, 3, 5 These agents provide cardio-renal protection beyond glycemic control and should take priority over other oral agents in this population.
For Patients WITHOUT High-Risk Comorbidities:
Consider adding one of the following oral agents to metformin, selecting based on patient-specific factors: 1
- Sulfonylurea (e.g., glipizide, glimepiride)
- Thiazolidinedione (e.g., pioglitazone)
- SGLT-2 inhibitor (e.g., empagliflozin, dapagliflozin, canagliflozin)
- DPP-4 inhibitor (e.g., sitagliptin, linagliptin, saxagliptin)
Factors Guiding Second-Agent Selection
Discuss the following with each patient before selecting a second agent: 1
Hypoglycemia risk: Sulfonylureas carry significant hypoglycemia risk; DPP-4 inhibitors and SGLT-2 inhibitors do not cause hypoglycemia as monotherapy or with metformin. 1
Weight impact: SGLT-2 inhibitors promote weight loss; sulfonylureas and thiazolidinediones cause weight gain. 1
Cost: Sulfonylureas are inexpensive; SGLT-2 inhibitors and DPP-4 inhibitors are significantly more costly. 1
Side effect profile: Thiazolidinediones increase fracture risk and may cause edema; SGLT-2 inhibitors increase genital mycotic infections and urinary tract infections. 1
Common Pitfalls and How to Avoid Them
Gastrointestinal Intolerance
If gastrointestinal side effects occur during titration, decrease to the previous lower dose and attempt to advance again after 1-2 weeks. 2 Alternatively, switch from immediate-release to extended-release metformin, which improves tolerability. 2, 6
Failure to Monitor Renal Function
Always check eGFR before initiating metformin and never assume stable renal function in elderly patients or those with diabetes complications. 3 Failure to monitor leads to drug accumulation and increased lactic acidosis risk. 7, 4
Premature Treatment Intensification
Do not add a second agent before 3 months on optimized metformin therapy unless severe hyperglycemia is present. 2 Many patients achieve target A1c with metformin monotherapy if given adequate time and proper dosing.
Ignoring Cardiovascular and Renal Comorbidities
For patients with established ASCVD, heart failure, or CKD, prioritize SGLT-2 inhibitors or GLP-1 receptor agonists over other second-line agents regardless of cost considerations, as these provide mortality and morbidity benefits beyond glucose lowering. 2, 3, 5
Vitamin B12 Deficiency
Screen for vitamin B12 deficiency in long-term metformin users (>4 years), particularly those with unexplained anemia or new-onset peripheral neuropathy. 2, 3, 6 This is a frequently overlooked complication that can mimic diabetic neuropathy.